INCY News and Press, Incyte Corporation From 10/21/21

Eli Lilly (NYSE: LLY) and Incyte 's (NASDAQ: INCY) drug, Olumiant, has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to treat hospitalized COVID-19 patients with or without remdesivir. While the EUAs for Olumiant to be used as bo...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy delivered positive returns and outperformed ...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated, 6 stocks were removed and 6 added from the u...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q2-2021 13F filings the consensus holdings were updated, 6 stocks were removed and 6 added from the unive...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

- Treatment with ruxolitinib cream (Opzelura™) resulted in facial repigmentation at Week 24, characterized by a significant proportion of patients achieving ≥75% improvement from baseline in the facial Vitiligo Area Scoring Index - A significantly greater proport...

Incyte (Nasdaq:INCY) today announced the full 24-week results from its pivotal Phase 3 TRuE-V clinical trial program investigating ruxolitinib cream (Opzelura ), a topical JAK inhibitor, in adolescent and adult patients (age ≥12 years) with nonsegmental vitiligo. These data will be p...

4 Trending Biotech Stocks For Your List Of Stocks This Month Biotech stocks are among some of the most intriguing investments in the stock market . This is an industry that includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medica...

The following slide deck was published by Incyte Corporation in conjunction with this event. For further details see: Incyte (INCY) GVHD Update Presentation - Slideshow

OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata - Potential first-in-disease treatment for millions of adults worldwide living with alopecia areata (AA) - - Saf...